For the first evaluation, we verified the in vivo efficacy of single doses of 30 mg/Kg/day GLPG1790 in mice by using three human models of high-grade glioma cells (U87MG, U251 and T98G) grown as subcutaneous xenografts and showing different levels of EphA2. The gene discussed is EPHA2; the disease is glioma.